MDWD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MediWound Ltd (MDWD) does not present a strong buy opportunity for a beginner, long-term investor at this time. While there are positive developments in its product pipeline, the company's financial performance and lack of significant trading signals suggest it is better to wait for clearer signs of growth or stability.
The MACD is above 0 and positively contracting, indicating mild bullish momentum, but RSI is neutral at 47.017, showing no clear trend. Moving averages are converging, and the stock is trading near its pivot level of 16.976, with resistance at 17.977 and support at 15.975. Overall, the technical indicators suggest a neutral trend.
A U.S. expert panel's support for MediWound's EscharEx® as an innovative treatment for chronic wounds could drive future growth and investor interest.
The company's financials show significant revenue decline (-68.03% YoY) and a negative net income, despite some improvement in EPS. Gross margin has also dropped slightly. Additionally, options data shows bearish sentiment, and there are no recent insider or hedge fund buying trends.
In Q4 2025, revenue dropped significantly (-68.03% YoY) to $1.867M. Net income improved to -$7.183M (up 83.80% YoY), and EPS increased to -0.56 (up 55.56% YoY). However, gross margin declined to 14.89% (-3.69% YoY), indicating ongoing financial challenges.
No recent analyst rating or price target changes were provided. Wall Street sentiment appears neutral.
